KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study.

Martin Köhrmann, Jörg Berrouschot, Joaquín Serena, Natan M Bornstein, Helle K Iversen, Dheeraj Kalladka, Georgi Krastev, Carlos A Molina, André Peeters, Daniel Šaňák, Igor P Sibon, Lucie Della Schiava, José I Tembl, Jaime Masjuan, Hassan Soda, Sébastien Richard, Zuzana Eichlova, Alexandra L Czap, Gilles Avenard, Sophie Binay, Sirine Bougamra, Andrea Comenducci, Elodie Drumez, Adeline Meilhoc, Yannick Pletan, Anouar Sari, Elie Toledano, Jean-Marie Grouin, James C Grotta, ACTISAVE Study Group

Stroke 57(5) 1116-1125

PMID42044230
PMCIDPMC13117549
DOI10.1161/STROKEAHA.125.052935
发表日期2026-04-27
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2.:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Glenzocimab, a platelet glycoprotein VI antagonist, is a novel agent that inhibits platelet activation and aggregation. Its safety was demonstrated in the ACTIMIS trial (Acute Ischemic Stroke Interventional Study; URL: https://www.clinicaltrials.gov; Unique identifier: NCT03803007) for patients with stroke receiving thrombolysis, with or without mechanical thrombectomy, and results suggested a reduction in intracranial hemorrhages and mortality. The ACTISAVE trial was designed as a confirmatory study to evaluate the efficacy and safety of glenzocimab in acute ischemic stroke. METHODS: ACTISAVE (Acute Ischemic Stroke Study Evaluating Glenzocimab Used as Add-On Therapy Versus Placebo) was an international, randomized, double-blind, placebo-controlled phase 2/3 study in patients with stroke, treated by thrombolysis within 4.5 hours of symptoms onset with or without mechanical thrombectomy. The study was conducted at 54 primary and comprehensive stroke centers located in 10 countries. Patients were randomized 1:1 to glenzocimab (1000 mg-IV) or placebo. The primary outcome was the modified Rankin Scale (mRS) score of 4 to 6 at day 90. Key secondary outcome was the mRS score of 0 to 2 at day 90. Mortality, mRS shift, National Institutes of Health Stroke Scale score, quality of life, and safety outcomes were assessed. RESULTS: Between September 2021 and October 2023, 438 patients were randomized, 421 treated, and included as randomized in the primary analysis set. Median age was 73 (63-80) years, and 43% were female. Thrombolysis was performed 2.3 hours (median) after symptom onset and followed by mechanical thrombectomy in 36% of patients. The assigned treatment began a median of 1.2 (interquartile range, 0.8-1.6) hours after thrombolysis initiation. Prethrombolysis National Institutes of Health Stroke Scale score median was 9 (6-15). At day 90, there was no statistically significant difference in the primary outcome between the treatment groups: the incidence of poor outcome (mRS score 4-6 versus 0-3) was 21.6% in the glenzocimab group compared with 15.3% placebo group (odds ratio, 1.51 [95% CI, 0.90-2.54]; P=0.120). No statistically significant difference in secondary outcomes was observed. There were no major safety signals with any intracerebral hemorrhage occurring respectively in 60 (28.6%) and 63 (29.9%) patients in glenzocimab and placebo arms. CONCLUSIONS: ACTISAVE failed to confirm a beneficial effect of glenzocimab on mRS in patients with acute ischemic stroke treated by thrombolysis. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05070260.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Study overview (CONSORT diagram). Completers set is defined as patients with an evaluation of modified Rankin Scale (mRS) score at day 90. Lost-to-follow-up patients were included in the full analysis set by using multiple implementations of the mRS score at day 90. AE indicates adverse events; CONSORT, Consolidated Standards of Reporting Trials; and IMP, Investigational Medicinal Products.
非 KM Figure
Figure 2.Primary end point results: modified Rankin Scale (mRS) at day 90. A , mRS scores at 3 months by study treatment group. B , Primary outcome: poor outcome odds ratio (OR) at 3 months. A , Only patients with mRS score data are shown—completers set. B , OR were calculated on the full analysis set. Missing mRS scores were imputed using a mixture of worst-case imputation and missing at random multiple imputation techniques. Treatment effect and P values are presented after handling missing values. OR was also evaluated in prespecified subgroups according to standard-of-care, baseline severity, and age at screening. MAR indicates missing at random; NIHSS, National Institutes of Health Stroke Scale; and p het, P value for heterogeneity.
非 KM Figure